Risk and exposure
Review modality, target, expected exposure and known class risk.
Application
Human organoid safety & toxicology
Use human organ models to compare dose- and exposure-related injury with organ-specific morphological, functional and molecular readouts.
Human organ safety studies
Build a multi-organ safety study from lung and kidney evidence
Match lung, kidney, gastric and adjacent non-tumor liver models to the candidate’s expected exposure and organ risks, with tailored QC, dosing conditions and injury endpoints for each tissue.
View imageAlveolar endpoints: normal and LPS conditions are compared through bright-field, AT1, AT2, DAPI and merged views, connecting the injury condition with alveolar-cell profiling.
TRiCBIO normal-lung organoid LPS injury study
View imageH9-derived | cisplatin molecular response: RT-qPCR profiles KIM-1, H2AFX and inflammation/stress-related genes across cisplatin conditions, helping prioritize kidney-injury biomarkers and define follow-on dose, timing and confirmatory assays.
TRiCBIO H9-derived kidney organoid cisplatin studyReview the full study
Continue to the related case for model context, experimental setup and interpretation.
Study focus
What this study can help you decide
- 01Which organs or cell types are most affected?
- 02How do morphology, viability and molecular injury support one another?
- 03How do dose and exposure define an interpretable window?
Study workflow
How the study moves from question to results
Normal-model QC
Confirm organ and cell identity to establish a reliable baseline for interpreting candidate-related injury.
Dose and injury endpoints
Combine morphology, viability, histology and molecular injury readouts.
Injury-response window and study extension
Compare in vitro injury trends and prioritize signals for mechanism work or confirmation in another model.
Model options
Match the model to indication, mechanism and sample
Start with kidney molecular-injury and normal-lung LPS-injury evidence, then extend to gastric and adjacent non-tumor liver organoids according to candidate risk, with organ-specific QC, exposure conditions and injury endpoints planned together.
PROJECT DISCUSSION
Plan a human organoid safety study
Candidate exposure, priority organ risks and available safety findings guide human organ-model selection, dose design and organ-specific injury endpoints.